Tvardi Therapeutics, Inc. (NASDAQ:TVRD - Get Free Report) shares rose 2.4% during trading on Thursday . The company traded as high as $22.85 and last traded at $22.67. Approximately 19,929 shares were traded during trading, a decline of 77% from the average daily volume of 87,609 shares. The stock had previously closed at $22.13.
Analysts Set New Price Targets
TVRD has been the subject of a number of analyst reports. Wall Street Zen raised shares of Tvardi Therapeutics to a "hold" rating in a report on Saturday, May 24th. Piper Sandler initiated coverage on shares of Tvardi Therapeutics in a report on Thursday, June 12th. They set an "overweight" rating and a $78.00 target price for the company. Finally, Oppenheimer initiated coverage on shares of Tvardi Therapeutics in a report on Wednesday, May 21st. They set an "outperform" rating and a $65.00 target price for the company.
Check Out Our Latest Research Report on TVRD
Tvardi Therapeutics Trading Up 2.4%
About Tvardi Therapeutics
(
Get Free Report)
Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tvardi Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tvardi Therapeutics wasn't on the list.
While Tvardi Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
